Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

ABSTRACT:

Importance

Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial.

Objective

To determine 2-year overall survival (OS) using perioperative chemotherapy for resectable PDA.

Design, setting, and participants

This was a randomized phase 2 trial of perioperative chemotherapy with a pick-the-winner design. It was conducted across the National Clinical Trials Network, including academic and community centers all across the US. Eligibility required patients with Zubrod Performance Score of 0 or 1, confirmed tissue diagnosis of PDA, and resectable disease per Intergroup criteria.

SUBMITTER: Sohal DPS 

PROVIDER: S-EPMC7821078 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature